companies

CMR Surgical is developing a next-generation universal robotic system for minimal access surgery. The company's vision is to make minimal access surgery universally accessible and affordable by significantly expanding the range of procedures that can be performed robotically. Global annual revenues for robot-assisted minimal access surgery are presently approximately $4 billion and are anticipated to reach $20 billion by 2025.

Bicycle Therapeutics is developing a unique class of chemically synthesized medicines based on its proprietary bicyclic peptide (Bicycle®) product platform to address therapeutic needs unreachable with existing treatment modalities. Bicycle’s internal focus is in oncology, where the company is developing targeted cytotoxics (Bicycle Toxin Conjugates), targeted innate immune activators and T-cell modulators for cancers of high unmet medical need.

Clinical-stage biopharmaceutical company developing a deep pipeline of novel human antibody-based therapies in a broad range of indications. Kymab’s platforms generate a vast repertoire of fully-human, species cross-reactive and affinity-matured antibodies against challenging targets

Developer of novel bispecific antibody products focused on immuno-oncology. The Modular Antibody Technology allows for the rapid discovery and development of bispecific antibodies by introducing additional binding sites to the constant region of an antibody.

Artios is engaged in the development of novel cancer treatments designed to target the DNA Damage Response (DDR).

Microbiotica has been established to commercialise ground-breaking research, conducted in the Host-Microbiota Interactions Laboratory (HMIL) at the Sanger Institute, into the role of the human microbiome in health and disease and its application to medicine. The Sanger Institute teams have made significant breakthroughs in the analysis and understanding of the human microbiome, combining an extensive DNA sequencing capability with novel culturing methods to build a first-in-class gut microbiome culture collection and reference genome library.

Healx integrates artificial intelligence with expert pharmacology to discover new treatments for rare diseases and to accelerate them into clinical trials.

Gyroscope is developing cutting edge, genetically defined therapies for the treatment of eye diseases linked to an unbalanced complement system, which is a part of the immune system. It is exploring the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of age-related macular degeneration (AMD) and gene therapy as a mode of treatment delivery.

Mogrify® represents a unique opportunity to transform the development of ex vivo cell therapies, as well as pioneer a new class of in vivo reprogramming therapies for diseases with high unmet clinical need.

Congenica is a digital health company enabling automated analysis and interpretation of complex genomic data, empowering health professionals to provide life-changing answers that transform the lives of patients and their families.

The Raspberry Pi Foundation is a UK-based educational charity that works to put the power of computing and digital making into the hands of people all over the world. Established in 2008 and first known for our product - the wildly successful Raspberry Pi computer - the Foundation has developed educational content and programmes that are reaching millions of people worldwide. We are now the 3rd most popular computing platform in the world after the PC and Apple and represent one of the largest, sustained global efforts to help young people learn computing.

Darktrace’s pioneering technology, the Enterprise Immune System, applies AI to the cyber defence challenge for the first time, and has proven itself successful in detecting cyber-threats that existing, legacy systems cannot.

Developer of flexible integrated circuits (FlexICs) that are thinner than a human hair and can be easily embedded into everyday objects within the consumer goods, games, retail, pharmaceutical and security sectors. PragmatIC’s solutions provide the opportunity to add new functionality to items, as well as extending proven applications such as RFID and NFC into mass-market use cases that were previously prohibited by the cost of traditional silicon integrated circuits.

Provider of an autonomous vehicle software designed to drive vehicles safely without the need for a human behind the wheel. The company's AI-powered system uses multiple sensors around the vehicle, providing a view of the environment to predict, plan and safely navigate urban environments enabling benefits such as increased safety, reduced congestion, shorter journey times and cleaner air.

Developer of data processing and edge analytics software designed to deliver powerful real-time business and operational insights. The company's software uses machine learning and edge computing to process streaming data as it is generated in real-time at the edge without needing a message broker or central databases.

Developer of a risk analytics platform intended to transform underwriting for commercial insurance. The company's platform leverages artificial intelligence to learn the patterns of different risks and loss outcomes over time and computes a rank, score and price for every property and company, enabling insurers to target the most profitable risks, improve risk selection and pricing as well as deliver fairer prices to their customers.

Developer of an adaptive behavioural analytics platform designed to bring novel insights through new ways of treating data. The company's platform monitors all customer data in real-time to spot anomalies and block new fraud attacks as they occur and recognises genuine customers without blocking their activity, enabling organisations to reduce their fraud costs, keep their customers happy and increase their revenues.

Developer of quantum computing software intended to transform the discovery of new materials and drugs. The company's offerings include a simulation engine for microscopic systems that accurately accounts for quantum effects, enabling businesses to apply quantum computing disruptively within their organisation and industry.

Provider of an artificial intelligence (AI) platform intended to speed up development times in areas such as drug discovery and material design. The company's platform offers proprietary algorithms which enable neural networks to be trained on a fragmented or incomplete database, enabling clients to analyse significantly more data than traditional artificial intelligence approaches required for drug discovery and material design.

GeoSpock DB is the space-time analytics database that brings sensor data to life, harnessing trillions of data points to rapidly translate real-world complexity into valuable commercial insights.

Telensa PLANet® is the world’s most deployed smart streetlight solution, with a footprint of 2 million lights. Telensa’s Urban IQ system builds on the compelling business case for smart street lighting to provide cities and utilities with an open, low-cost platform to add multiple sensor applications.

Telensa is based in Cambridge in the UK, and manufactures with Sony UK Tech in Pencoed, Wales. We also have regional operations in the USA and Australia.

Kao Data operate an industrial scale data centre campus close to Cambridge. We provide a resilient, scalable and sustainable home for Cambridge’s high performance computing demands.